Valuation models
price $697.00 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused286.10 – 451.49352.8398% overvaluedDCF · Perpetuity growth · 10y330.06 – 508.83402.3573% overvaluedDCF · EBITDA exit · 5y800.55 – 880.09839.2317% undervaluedDCF · EBITDA exit · 10y741.43 – 884.73809.5914% undervaluedP/E · peers638.41 – 802.99696.89at modelP/E · own history607.54 – 754.12661.945% overvaluedPEG—406.8071% overvaluedEV/EBITDA · peers541.83 – 830.92754.118% undervaluedEV/Revenue · peers539.66 – 911.77666.775% overvaluedEarnings power value117.25 – 204.71152.96356% overvaluedDividend discount34.47 – 79.6051.051265% overvaluedWall St. consensus target—752.007% belowCost of capital (WACC)—8.19%—
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
352.83
Thermo Fisher Scientific closed at $697.00 — overvalued by 98% vs model.
286.10the model's range451.49
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
51.05 – 839.23
Wall St. target
752.00 7% below
Above model, 1y
31 of 31 days
How it is valued
Valued asMature & Stable
Low/slowing growth (~2% recent)Moderate margins (15% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.